Semi-Annual Report — FY2026 H1
What Otsuka Holdings Co.,Ltd. reported for the period from 2026-01-01 to 2026-12-31.
Filed 2026-07-31View the original on EDINET
How much it says
63Detailed
What moved here
39named for the first time
Its own wording
38terms
Which filing this is
37/ 37newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
During the interim consolidated accounting period, revenue and R&D expenses increased. The consolidation scope also expanded through the establishment of Otsuka Clinical Nutrition America LLC in the healthcare segment and the acquisition of Transcend Therapeutics, Inc. as a subsidiary.
Komori's summary of this document, not the document's own words.63Detailed
How much this filing saysA weighted roll-up of 11 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 36 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
73
Detailed
61
Detailed
89
Very detailed
62
Detailed
0
Almost nothing
68
Detailed
69
Detailed
100
Very detailed
53
Typical
55
Typical
50
Typical
R&D spend1,722億円Money spent making new things.
Cash left over441億円Cash from the business, less what went into equipment.
Spent on equipment1.4兆円Plants, machines — things meant to last.
EmployeesNot disclosedThis document does not carry the figure.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.